Novel and Investigational Treatments for Onychomycosis
暂无分享,去创建一个
[1] M. Shams-Ghahfarokhi,et al. Prevalence, genetic diversity and antifungal susceptibility profiles of F. fujikuroi, F. solani and Fusarium incarnatum‐equiseti species complexes from onychomycosis in north of Iran , 2022, Mycoses.
[2] A. Concheiro,et al. Poly(pseudo)rotaxanes formed by mixed micelles and α-cyclodextrin enhance terbinafine nail permeation to deeper layers , 2022, International journal of pharmaceutics: X.
[3] R. Fuhr,et al. Results from a Phase 1/2 trial of BB2603, a terbinafine‐based topical nano‐formulation, in onychomycosis and tinea pedis , 2022, Mycoses.
[4] S. Hashemi,et al. The epidemiology and etiology of onychomycosis in 2 laboratory centers affiliated to Tehran university of medical sciences during 2019–2020 , 2022, Iranian journal of microbiology.
[5] B. Piraccini,et al. Onychomycosis: Recommendations for Diagnosis, Assessment of Treatment Efficacy, and Specialist Referral. The CONSONANCE Consensus Project , 2022, Dermatology and Therapy.
[6] Aditya K. Gupta,et al. Efinaconazole in Onychomycosis , 2021, American Journal of Clinical Dermatology.
[7] S. Bunyaratavej,et al. Effectiveness and safety of topical amphotericin B in 30% dimethyl sulfoxide cream versus 30% dimethyl sulfoxide cream for nondermatophyte onychomycosis treatment: A pilot study , 2021, Indian Journal of Dermatology, Venereology and Leprology.
[8] Aditya K. Gupta,et al. 27602 Long-term efficacy and safety of once-daily topical efinaconazole 10% topical solution (Jublia) for dermatophyte toenail onychomycosis: An interim analysis , 2021 .
[9] A. Firooz,et al. The in vitro effect of nanoliposomal amphotericin B against two clinically important dermatophytes , 2021, International journal of dermatology.
[10] E. Egito,et al. Polishing the Therapy of Onychomycosis Induced by Candida spp.: Amphotericin B–Loaded Nail Lacquer , 2021, Pharmaceutics.
[11] M. Venkataraman,et al. Nondermatophyte mould onychomycosis , 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.
[12] E. Ghelardi,et al. In Vitro Resistance and Evolution of Resistance to Tavaborole in Trichophyton rubrum , 2021, Antimicrobial Agents and Chemotherapy.
[13] Aditya K. Gupta,et al. Long-term Efficacy and Safety of Once-daily Efinaconazole 10% Topical Solution (Jublia) for Dermatophyte Toenail Onychomycosis: An Interim Analysis. , 2021, Skin therapy letter.
[14] Aditya K. Gupta,et al. Efficacy and safety of topical terbinafine 10% solution (MOB-015) in the treatment of mild-to-moderate distal subungual onychomycosis: A randomized, multi-center, double-blind, vehicle-controlled phase 3 study. , 2020, Journal of the American Academy of Dermatology.
[15] D. Mercer,et al. NP213 (Novexatin®): A unique therapy candidate for onychomycosis with a differentiated safety and efficacy profile , 2020, Medical mycology.
[16] D. Monti,et al. Ciclopirox and Efinaconazole Transungual Permeation, Antifungal Activity, and Proficiency To Induce Resistance in Trichophyton rubrum , 2019, Antimicrobial Agents and Chemotherapy.
[17] D. Mercer,et al. Improved Methods for Assessing Therapeutic Potential of Antifungal Agents against Dermatophytes and Their Application in the Development of NP213, a Novel Onychomycosis Therapy Candidate , 2019, Antimicrobial Agents and Chemotherapy.
[18] Y. Kuwano,et al. Retrospective Survey of Treatment Outcomes of Efinaconazole 10% Solution and Luliconazole 5% Solution for Onychomycosis in Our Facility. , 2019, Medical mycology journal.
[19] R. Mays,et al. Global perspectives for the management of onychomycosis , 2018, International journal of dermatology.
[20] H. Badali,et al. Low In Vitro Antifungal Activity of Tavaborole against Yeasts and Molds from Onychomycosis , 2018, Antimicrobial Agents and Chemotherapy.
[21] S. Lipner,et al. Evaluation of the efficacy and safety of tavaborole topical solution, 5%, in the treatment of onychomycosis of the toenail in adults: a pooled analysis of an 8-week, post-study follow-up from two randomized phase 3 studies , 2018, The Journal of dermatological treatment.
[22] H. Maibach,et al. In Vitro Human Onychopharmacokinetic and Pharmacodynamic Analyses of ME1111, a New Topical Agent for Onychomycosis , 2017, Antimicrobial Agents and Chemotherapy.
[23] H. Kishida,et al. Efficacy and safety of luliconazole 5% nail solution for the treatment of onychomycosis: A multicenter, double‐blind, randomized phase III study , 2017, The Journal of dermatology.
[24] H. Maibach,et al. Antifungal ME1111 in vitro human onychopharmacokinetics , 2017, Drug development and industrial pharmacy.
[25] B. Piraccini,et al. Onychomycosis in patients with nail psoriasis: a point to point discussion , 2017, Mycoses.
[26] Aditya K. Gupta,et al. Tavaborole – a treatment for onychomycosis of the toenails , 2016, Expert review of clinical pharmacology.
[27] N. Kubota,et al. [Distribution of Luliconazole in Nail Plate by In Vitro Permeation and Efficacy by Zone of Inhibition Test after Treatment of Luliconazole Nail Solution]. , 2016, Medical mycology journal.
[28] S. Abe,et al. Mechanism of Action of ME1111, a Novel Antifungal Agent for Topical Treatment of Onychomycosis , 2015, Antimicrobial Agents and Chemotherapy.
[29] B. Elewski,et al. Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studies. , 2015, Journal of the American Academy of Dermatology.
[30] T. Rosen,et al. Onychomycosis: epidemiology, diagnosis, and treatment in a changing landscape. , 2015, Journal of drugs in dermatology : JDD.
[31] B. Sigurgeirsson,et al. The prevalence of onychomycosis in the global population – A literature study , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.
[32] J. Lear,et al. British Association of Dermatologists' guidelines for the management of onychomycosis 2014 , 2014, The British journal of dermatology.
[33] J. Ocampo-Candiani,et al. The efficacy and safety of tavaborole, a novel, boron-based pharmaceutical agent: phase 2 studies conducted for the topical treatment of toenail onychomycosis. , 2014, Journal of drugs in dermatology : JDD.
[34] N. Zaias,et al. Opportunistic toenail onychomycosis. The fungal colonization of an available nail unit space by non‐dermatophytes is produced by the trauma of the closed shoe by an asymmetric gait or other trauma. A plausible theory , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.
[35] Aditya K Gupta,et al. LUZU (luliconazole) 1% cream. , 2014, Skinmed.
[36] Y. Ohno,et al. Onychomycosis as a warning sign for peripheral arterial disease. , 2013, Acta dermato-venereologica.
[37] B. Elewski,et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies. , 2013, Journal of the American Academy of Dermatology.
[38] J. Olin,et al. Efinaconazole solution in the treatment of toenail onychomycosis: a phase 2, multicenter, randomized, double-blind study. , 2013, Journal of drugs in dermatology : JDD.
[39] K. Capriotti,et al. Dimethyl sulfoxide: history, chemistry, and clinical utility in dermatology. , 2012, The Journal of clinical and aesthetic dermatology.
[40] J. Appel,et al. The asymmetric gait toenail unit sign. , 2012, SKINmed Dermatology for the Clinician.
[41] R. Baran. The nail in the elderly. , 2011, Clinics in dermatology.
[42] B. Piraccini,et al. Long-term follow-up of toenail onychomycosis caused by dermatophytes after successful treatment with systemic antifungal agents. , 2010, Journal of the American Academy of Dermatology.
[43] O. Pourquié,et al. Rere controls retinoic acid signalling and somite bilateral symmetry , 2010, Nature.
[44] M. A. Randhawa. Dimethyl sulfoxide (DMSO) inhibits the germination of Candida albicans and the arthrospores of Trichophyton mentagrophytes. , 2008 .
[45] Muhammad Akram Randhawa. Dimethyl sulfoxide (DMSO) inhibits the germination of Candida albicans and the arthrospores of Trichophyton mentagrophytes. , 2008, Nihon Ishinkin Gakkai zasshi = Japanese journal of medical mycology.
[46] H. Maibach,et al. In Vitro penetration of a novel oxaborole antifungal (AN2690) into the human nail plate. , 2007, Journal of pharmaceutical sciences.
[47] B. Sigurgeirsson,et al. Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. , 2002, Archives of dermatology.
[48] B. Piraccini,et al. Relapses of Onychomycosis after Successful Treatment with Systemic Antifungals: A Three-Year Follow-Up , 1998, Dermatology.
[49] J. Leyden,et al. Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial. , 1997, Journal of the American Academy of Dermatology.
[50] A. Tosti,et al. Autosomal dominant pattern of distal subungual onychomycosis caused by Trichophyton rubrum. , 1996, Journal of the American Academy of Dermatology.